Agencia Española de Medicamentos y Productos Sanitarios

C/Campezo 1, Edificio 8
28022 – Madrid
España
(Reference Member State)

MUTUAL RECOGNITION PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

AQUACEN OXITETRACICLINA HIDROCLORURO 1000 MG/G PREMEZCLA MEDICAMENTOSA

CORREO ELECTRÓNICO

mresvet@aemps.es

C/ CAMPEZO, 1 – EDIFICIO 8
28022 MADRID
TEL: 91 822 54 01
FAX: 91 822 5443

MODULE 1

PRODUCT SUMMARY

EU Procedure number	ES/V/0229/001/MR
Name, strength and pharmaceutical form	AQUACEN OXITETRACICLINA HIDROCLORURO 1000 mg/g PREMEZCLA MEDICAMENTOSA (ES) AQUACEN OXYTETRACYCLINE HYDROCHLORIDE 1000 mg/g MEDICATED PREMIX (EL, PT) OSSITETRACICLINA CENAVISA 1000 mg/g premix for medicated feeding stuff (IT)
Applicant	CENAVISA, S.L. Camí Pedra Estela s/n 43205 Reus (SPAIN)
Active substance(s)	Oxytetracycline hydrochloride
ATC Vet code	QJ01AA06
Target species	Salmonids (Salmo sp, Oncorhynchus sp), seabass (Dicentrarchus labrax), sea bream (Sparus aurata), turbot (Psetta maxima), european eel (Anguilla anguilla), european carp (Cyprinus carpio)
Indication for use	For the treatment of infections due to *Lactococcus garvieae* (lactococcosis), *Aeromonas hydrophila* (aeromoniosis) *and Vibrio anguillarum* (vibriosis) sensitive to oxytetracycline

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies website (http://www.hma.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Mutual Recognition application in accordance with Article 13(3) of Directive 2001/82/EC as amended.
Date of completion of the original mutual recognition procedure	24/12/2014
Date product first authorised in the Reference Member State (MRP only)	25/09/2014
Concerned Member States for original procedure	EL, IT, PT

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species.
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Composition

The product only contains oxytetracycline hydrochloride 1000 mg/g.

The container/closure system consists of four-layer heat-sealed bags containing 20 kg. The outermost layer of the bag is polyester, and the innermost layer is linear polyethylene coextrusion of low-medium density.
The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation is justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is oxytetracycline hydrochloride, an established substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Certificate of suitability from the manufacturer of active substance are provided.

D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies

Certificate of suitability issued by the EDQM have been provided and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

E. Control on intermediate products

Not applicable.

F. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production sites have been provided demonstrating compliance with the specification.

G. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life (2 years) when stored under the approved conditions.

The claim of 3 months stability after opening and after incorporation into pelleted feed is based on the demonstration of stability for batches stored 25 ± 2 °C.

H. Genetically Modified Organisms

The product does not contain genetically modified organisms.

J. Other Information

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACOTOXICOLOGICAL)

As this is a hybrid application according to Article 13(3), and bioequivalence with a reference product has been demonstrated, results of safety and residue tests are not required.

The safety aspects of this product are identical to the reference product.

Warnings and precautions as listed on the product literature are the same as those of the reference product and are adequate to ensure safety of the product to users, the environment and consumers.

III.A Safety Testing

Pharmacological Studies

Since this is a hybrid application and the bioequivalence with the reference product has been demonstrated, the applicant is not required to provide the results of pharmacological trials.

Toxicological Studies

Since this is a hybrid application and the bioequivalence with the reference product has been demonstrated, the applicant is not required to provide the results of toxicological trials.

User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline which shows that implementing the indicated protective measures the use of the product poses an acceptable risk.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Ecotoxicity

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that further assessment was required with a second phase. The assessment concluded that the product does not pose a risk for the environment when it is used as recommended in the SPC.

Warnings and precautions as listed on the product literature are adequate to ensure safety to the environment when the product is used as directed.

III.B Residues documentation

Residue Studies

No residue depletion studies were conducted because this is a hybrid application and the bioequivalence with the reference product has been demonstrated.

MRL

Oxytetracycline is listed in Annex of Commission Regulation 37/2010 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuff of animal origin.

MRL are listed below:

Marker residue	Animal species	MRL	Target tissues	Other provisions
Sum of parent drug and its 4-epimer	All-food Producing species	100 µg/kg 300 µg/kg 600 µg/kg 100 µg/kg 200 µg/kg	Muscle Liver Kidney Milk Eggs	For fin fish the muscle MRL relates to muscle and skin in natural proportions. MRL for fat, liver and kidney do not appy to fin fish.

Withdrawal Periods

Based on the data provided above, a withdrawal period of 300 degree days for meat fish is justified.

IV. CLINICAL ASSESSMENT (EFFICACY)

This is a hybrid application according to Article 13(3) of Directive 2001/82/EC, amended by Directive 2004/28/EC. Bioequivalence with a reference product has been demonstrated, efficacy studies are not required and bibliographic information regarding different aspects related to the efficacy part was submitted. The efficacy claims for this product are equivalent to those of the reference product.

IV.A Pre-Clinical Studies

As this was a hybrid application according to Article 13(3) of Directive 2001/82/EC, amended by Directive 2004/28/EC, and Bioequivalence with a reference product was demonstrated, pre-clinical studies are not required.

IV.B Clinical Studies

As this was a hybrid application according to Article 13(3) of Directive 2001/82/EC, amended by Directive 2004/28/EC, and Bioequivalence with a reference product was demonstrated, clinical studies are not required.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the veterinary Heads of Agencies website (www.hma.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

None